Header Logo

Connection

Michael Silverberg to CD4 Lymphocyte Count

This is a "connection" page, showing publications Michael Silverberg has written about CD4 Lymphocyte Count.
Connection Strength

4.127
  1. Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. AIDS Patient Care STDS. 2015 Jul; 29(7):370-8.
    View in: PubMed
    Score: 0.498
  2. Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):175-181.
    View in: PubMed
    Score: 0.208
  3. Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 06 01; 72(11):1900-1909.
    View in: PubMed
    Score: 0.189
  4. Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting. . 2019 07 01; 81(3):284-291.
    View in: PubMed
    Score: 0.166
  5. Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatol. 2017 09 01; 153(9):892-896.
    View in: PubMed
    Score: 0.146
  6. Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals. AIDS. 2017 04 24; 31(7):989-993.
    View in: PubMed
    Score: 0.142
  7. Higher Time-Updated Body Mass Index: Association With Improved CD4+ Cell Recovery on HIV Treatment. J Acquir Immune Defic Syndr. 2016 10 01; 73(2):197-204.
    View in: PubMed
    Score: 0.137
  8. Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention Among HIV-Infected Adults in North America. Am J Epidemiol. 2015 Dec 01; 182(11):952-60.
    View in: PubMed
    Score: 0.129
  9. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System. AIDS Patient Care STDS. 2015 Nov; 29(11):582-90.
    View in: PubMed
    Score: 0.129
  10. HIV infection and incidence of ischemic stroke. AIDS. 2014 Aug 24; 28(13):1911-9.
    View in: PubMed
    Score: 0.118
  11. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):160-6.
    View in: PubMed
    Score: 0.114
  12. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013 Mar 06; 105(5):350-60.
    View in: PubMed
    Score: 0.106
  13. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
    View in: PubMed
    Score: 0.105
  14. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):321-7.
    View in: PubMed
    Score: 0.102
  15. HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons. AIDS. 2011 Sep 10; 25(14):1771-7.
    View in: PubMed
    Score: 0.096
  16. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS. 2010 Jul 17; 24(11):1765-70.
    View in: PubMed
    Score: 0.089
  17. New insights into the role of HIV infection on cancer risk. Lancet Oncol. 2009 Dec; 10(12):1133-4.
    View in: PubMed
    Score: 0.085
  18. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009 Nov 13; 23(17):2337-45.
    View in: PubMed
    Score: 0.085
  19. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26.
    View in: PubMed
    Score: 0.081
  20. Do antiretrovirals reduce the risk of non-AIDS-defining malignancies? Curr Opin HIV AIDS. 2009 Jan; 4(1):42-51.
    View in: PubMed
    Score: 0.080
  21. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007 Sep 12; 21(14):1957-63.
    View in: PubMed
    Score: 0.073
  22. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS. 2006 Jul 13; 20(11):1531-8.
    View in: PubMed
    Score: 0.067
  23. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis. 2004 Sep 01; 39(5):717-24.
    View in: PubMed
    Score: 0.059
  24. Evaluation of mean corpuscular volume among anemic people with HIV in North America following ART initiation. AIDS Res Ther. 2024 Aug 07; 21(1):52.
    View in: PubMed
    Score: 0.059
  25. The changing prevalence of anemia and risk factors in people with HIV in North America who have initiated ART, 2007-2017. AIDS. 2023 02 01; 37(2):287-298.
    View in: PubMed
    Score: 0.052
  26. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis. 2002 Aug; 29(8):427-35.
    View in: PubMed
    Score: 0.051
  27. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study. Lancet HIV. 2022 03; 9 Suppl 1:S2.
    View in: PubMed
    Score: 0.050
  28. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021 02 01; 4(2):e2037512.
    View in: PubMed
    Score: 0.046
  29. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 04; 23(4):e25484.
    View in: PubMed
    Score: 0.044
  30. Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clin Infect Dis. 2020 03 03; 70(6):1176-1185.
    View in: PubMed
    Score: 0.043
  31. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2019 09 01; 82(1):71-80.
    View in: PubMed
    Score: 0.042
  32. Cervical cancer risk in women living with HIV across four continents: A multicohort study. Int J Cancer. 2020 02 01; 146(3):601-609.
    View in: PubMed
    Score: 0.041
  33. A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):548-553.
    View in: PubMed
    Score: 0.036
  34. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):568-576.
    View in: PubMed
    Score: 0.036
  35. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clin Infect Dis. 2017 Aug 15; 65(4):636-643.
    View in: PubMed
    Score: 0.036
  36. Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):382-390.
    View in: PubMed
    Score: 0.036
  37. Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing. J Infect Dis. 2017 08 01; 216(3):387-391.
    View in: PubMed
    Score: 0.036
  38. Novel tumor markers provide improved prediction of survival after diagnosis of human immunodeficiency virus (HIV)-related diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 02; 59(2):321-329.
    View in: PubMed
    Score: 0.036
  39. HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. Clin Infect Dis. 2017 02 15; 64(4):468-475.
    View in: PubMed
    Score: 0.035
  40. A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NA-ACCORD and CCASAnet clinical cohorts. J Int AIDS Soc. 2016; 19(1):20707.
    View in: PubMed
    Score: 0.033
  41. Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):50-8.
    View in: PubMed
    Score: 0.032
  42. Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010. HIV Med. 2015 Oct; 16(9):572-7.
    View in: PubMed
    Score: 0.031
  43. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol. 2014 Dec; 50(12):1169-76.
    View in: PubMed
    Score: 0.030
  44. Missed office visits and risk of mortality among HIV-infected subjects in a large healthcare system in the United States. AIDS Patient Care STDS. 2013 Aug; 27(8):442-9.
    View in: PubMed
    Score: 0.027
  45. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2012 Dec; 28(12):1630-6.
    View in: PubMed
    Score: 0.025
  46. Virologic and immunologic response to HAART, by age and regimen class. AIDS. 2010 Oct 23; 24(16):2469-79.
    View in: PubMed
    Score: 0.023
  47. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010 Jun 01; 50(11):1512-20.
    View in: PubMed
    Score: 0.022
  48. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):62-9.
    View in: PubMed
    Score: 0.021
  49. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90.
    View in: PubMed
    Score: 0.021
  50. Smoking enhances risk for new external genital warts in men. Int J Environ Res Public Health. 2009 03; 6(3):1215-34.
    View in: PubMed
    Score: 0.020
  51. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
    View in: PubMed
    Score: 0.020
  52. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008 Apr 23; 22(7):841-8.
    View in: PubMed
    Score: 0.019
  53. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS. 2008 Apr; 22(4):301-12.
    View in: PubMed
    Score: 0.019
  54. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):384-90.
    View in: PubMed
    Score: 0.019
  55. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):531-9.
    View in: PubMed
    Score: 0.018
  56. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005 Apr 20; 97(8):577-86.
    View in: PubMed
    Score: 0.015
  57. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA. 2005 Mar 23; 293(12):1471-6.
    View in: PubMed
    Score: 0.015
  58. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol. 2004 May; 190(5):1241-8.
    View in: PubMed
    Score: 0.014
  59. Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels. AIDS. 2001 Nov 09; 15(16):2101-8.
    View in: PubMed
    Score: 0.012

© 2024 Kaiser Permanente